1
|
Fang J, Lou S, Zhou X, Lou D, Zhou L, Bian R. Dihydromyricetin reverses capecitabine-induced peripheral myelin dysfunction through modulation of oxidative stress. Clin Exp Pharmacol Physiol 2024; 51:e13833. [PMID: 38302079 DOI: 10.1111/1440-1681.13833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 09/21/2023] [Accepted: 10/22/2023] [Indexed: 02/03/2024]
Abstract
Previous clinical reports have shown that capecitabine, an oral prodrug of 5-fluorouracil (5-Fu), can induce peripheral neuropathy, resulting in numbness, paresthesia and hypoesthesia. However, the mechanism through which capecitabine causes peripheral nerve injury remains unclear. Here, we demonstrate that systemic administration of capecitabine leads to myelin abnormalities in the peripheral nerves of mice, which are possibly attributed to the death of Schwann cells, the myelinating cells in the peripheral nervous system. Furthermore, our results show that 5-Fu induces significant oxidative stress in Schwann cells by inhibiting the expression of the anti-oxidative protein DJ-1, leading to a decrease in Schwann cell markers. We found that the anti-oxidant dihydromyricetin (DMY) reverses 5-Fu-induced Schwann cell death and oxidative stress and alleviates capecitabine-induced myelin abnormalities. Taken together, our data indicate that capecitabine induces peripheral myelin dysfunction by regulating DJ-1-mediated oxidative stress in Schwann cells and reveal DMY as a potential therapeutic strategy for capecitabine-induced peripheral neuropathy.
Collapse
Affiliation(s)
- Jie Fang
- Emergency Department, Zhoushan Hospital, Zhoushan, China
| | - Shuyi Lou
- National Computer Network Emergency Response Technical Team/Coordination Center of China, Beijing, China
| | | | - Dayong Lou
- Zhuji People's Hospital of Zhejiang Province, Shaoxin, China
| | - Liqin Zhou
- Zhuji People's Hospital of Zhejiang Province, Shaoxin, China
| | - Rong Bian
- Zhuji People's Hospital of Zhejiang Province, Shaoxin, China
| |
Collapse
|
2
|
Li H, Shan R, Ding J, Zhang J, Liu B, Ge Q, Cheng D, Li L, Zhang C, Su H, Li X, Li H, Ye J, Li H, Li F, Zhou H, Huo Q, Su Y. Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor. Expert Opin Drug Metab Toxicol 2023; 19:1015-1021. [PMID: 38059472 DOI: 10.1080/17425255.2023.2292735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Accepted: 11/29/2023] [Indexed: 12/08/2023]
Abstract
OBJECTIVES To compare the pharmacokinetic and safety of the test group capecitabine tablets (0.5 g) and the reference group capecitabine tablets (0.5 g). METHODS This study was registered at www.chinadrugtrials.org.cn under the registration number CTR20220138. 48 subjects with solid tumor were recruited and randomized to receive either the test group or the reference group at a dose of 2 g per cycle for three cycles of the entire trial. RESULTS The point estimate of the geometric mean ratio of Cmax for the subject and reference groups was 1.0670, which was in the range of 80.00%-125.00%. And the upper limit of 95% confidence interval was -0.0450 < 0. The statistics of geometric mean ratio of AUC0-t and AUC0-∞ (test group/reference group) and their 90% confidence intervals were in the range of 80.00%-125.00%, thus the test group was bioequivalent to the reference group under the conditions of this postprandial test. There were no major or serious adverse events. Conclusion: The pharmacokinetic profiles of capecitabine under postprandial conditions were consistent between the two groups. The two groups were bioequivalent and had a similar favorable safety profile in Chinese patients with solid tumor.
Collapse
Affiliation(s)
- Hongtao Li
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Rongfang Shan
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
| | - Jiaxiang Ding
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- School of Public Basic, Bengbu Medical College, Bengbu, Anhui, China
| | - Jialin Zhang
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Bingyan Liu
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Qin Ge
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Dongmei Cheng
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Lufeng Li
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Chaoyang Zhang
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - He Su
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Xiaoyue Li
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Huiru Li
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Jingjing Ye
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Hui Li
- Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Fengxian Li
- Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Huan Zhou
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
- School of Public Basic, Bengbu Medical College, Bengbu, Anhui, China
| | - Qiang Huo
- School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China
| | - Yue Su
- National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| |
Collapse
|
3
|
Ma H, Zhao N, Luo S, Zhang Y, Yuan Z, Sun H, Gao S, Zhan X, Zhang L. Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two-way crossover clinical trial. Eur J Pharm Sci 2023; 182:106373. [PMID: 36623698 DOI: 10.1016/j.ejps.2023.106373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 12/25/2022] [Accepted: 01/05/2023] [Indexed: 01/09/2023]
Abstract
OBJECTIVE The aim of this study was to examine the pharmacokinetics, bioequivalence, and safety of two tablet formulations of capecitabine 500 mg in Chinese patients with breast, colorectal or gastric cancer under fed condition. METHODS A multicentric, randomized, open-label, single-dose, two-period, two-way crossover trial was conducted by randomizing a single oral dose of test (T) or reference (R, Xeloda®) capecitabine (500 mg) to patients of either sex with colon, colorectal or breast cancer under fed condition (high-fat and high-calorie diet). Pharmacokinetic parameters were calculated using non-compartmental methods. Patients were monitored for safety and tolerability throughout the study. RESULTS 74 subjects were randomly enrolled. The T/R geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for Cmax, AUC0-t and AUC0-∞ of capecitabine were 96.60% (85.87-108.67%), 99.07% (95.40-102.89%), 99.17% (95.29-103.21%), respectively. All 90% CIs fell within the bioequivalence acceptance range of 80.00-125.00%. The common adverse events (AEs) included clinically significant laboratory abnormalities and gastrointestinal diseases. There were no serious adverse events (SAEs) or deaths during the study. No subject withdrew from the study due to AEs. CONCLUSION Single oral intake of test and the reference capecitabine tablets were bioequivalent under fed condition and had similar favourable safety profiles in Chinese patients with breast, colorectal or gastric cancer. TRIAL REGISTRATION chinadrugtrials.org.cn (CTR20182110).
Collapse
Affiliation(s)
- Haiping Ma
- Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, China
| | - Naping Zhao
- Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, China
| | - Suxia Luo
- Department of Gastroenterology, Henan Cancer Hospital, Zhengzhou, China
| | - Yanqiao Zhang
- Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China
| | - Zhijun Yuan
- Department of Oncology, Hunan Cancer Hospital, Changsha, China
| | - Hao Sun
- Department of Gastrointestinal Surgery, Chongqing University Cancer Hospital, Chongqing, China
| | - Shen Gao
- Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
| | - Xianbao Zhan
- Department of Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
| | - Li Zhang
- Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, China; Department of Pharmacy, The Second Hospital of Anhui Medical University, Hefei, China.
| |
Collapse
|
4
|
Li X, Cui D, Xiong J, Dang Q, Wen Q, Yan M, Li H, Jiang X, Lin C, Xie X, Wang T, Xiang L, Wang Y, Zheng L. Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients. Clin Pharmacol Drug Dev 2023; 12:324-332. [PMID: 36642942 DOI: 10.1002/cpdd.1202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 10/24/2022] [Indexed: 01/17/2023]
Abstract
The main objective of this study was to compare the pharmacokinetic (PK) bioequivalence of two capecitabine tablets and explore the different PK profiles of various tumors in Chinese patients with cancer. All 76 patients with a confirmed cancer diagnosis were included in this study. A single dose of 2000 mg of test or reference capecitabine (Xeloda, Hoffmann-La Roche) was orally administered postprandially. After 24 hours of washout, the patients were administered the test or the reference capecitabine alternately. PK samples were taken at the time of predose up to 6 hours postdose. Bioequivalence evaluation was performed using the geometric mean ratios of peak concentration in plasma (Cmax) , area under the concentration-time curve from time 0 to 6 h (AUC0-t) , and area under the concentration-time curve from time 0 to infinity (AUC0-∞ ) for capecitabine and 5-fluorouracil (5-FU). In this study, 90% confidence intervals of test/reference mean ratios of Cmax , AUC0-t , AUC0-∞ of capecitabine and 5-FU were in the range of 80%-125%. Both the test and reference capecitabine regimens were well tolerated in this study. Furthermore, we found that patients with esophageal-gastrointestinal cancers had higher exposure to capecitabine and a shorter time to Cmax (Tmax) than those with breast cancer. In conclusion, a single oral dose of 2000 mg of test capecitabine tablets after postprandial administration was bioequivalent to the reference drug.
Collapse
Affiliation(s)
- Xiaoyu Li
- Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Dongyang Cui
- Jiangsu Hengrui Medicine Co. Ltd., Lianyungang, Jiangsu, China
| | - Jianping Xiong
- Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
| | - Qi Dang
- Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China
| | - Qing Wen
- Jinan Central Hospital Affiliated to Shandong University, Jinan, China
| | - Min Yan
- Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China
| | - Hongxia Li
- Department of Pharmacology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China
| | - Xiaodong Jiang
- Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, China
| | - Cuihong Lin
- Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
| | - Xianhe Xie
- Department of Medical Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
| | - Teng Wang
- Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
| | - Lisha Xiang
- Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yongsheng Wang
- Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Li Zheng
- Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| |
Collapse
|
5
|
Shen X, Chen X, Lu J, Chen Q, Li W, Zhu J, He Y, Guo H, Xu C, Fan X. Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of ABCB1 gene polymorphism. Front Pharmacol 2022; 13:1037239. [PMID: 36506519 PMCID: PMC9733833 DOI: 10.3389/fphar.2022.1037239] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 11/17/2022] [Indexed: 11/26/2022] Open
Abstract
Objective: The aim of this study was to establish a population pharmacokinetic (PPK) model of valproic acid (VPA) in pediatric patients with epilepsy in southern China, and provide guidance for individualized medication of VPA therapy. Methods: A total of 376 VPA steady-state trough concentrations were collected from 103 epileptic pediatric patients. The PPK parameter values for VPA were calculated by using the nonlinear mixed-effects modeling (NONMEM) method, and a one-compartment model with first-order absorption and elimination processes was applied. Covariates included demographic information, concomitant medications and selected gene polymorphisms. Goodness-of-fit (GOF), bootstrap analysis, and visual predictive check (VPC) were used for model evaluation. In addition, we used Monte Carlo simulations to propose dose recommendations for different subgroup patients. Results: A significant effect of the patient age and ABCB1 genotypes was observed on the VPA oral clearance (CL/F) in the final PPK model. Compared with patients with the ABCB1 rs3789243 AA genotype, CL/F in patients with GG and AG genotypes was increased by 8% and reduced by 4.7%, respectively. The GOF plots indicated the satisfactory predictive performance of the final model, and the evaluation by bootstrap and VPC showed that a stable model had been developed. A table of individualized dosing regimens involving age and ABCB1 genotype was constructed based on the final PPK model. Conclusion: This study quantitatively investigated the effects of patient age and ABCB1 rs3789243 variants on the pharmacokinetic variability of VPA. The PPK models could be beneficial to individual dose optimization in epileptic children on VPA therapy.
Collapse
Affiliation(s)
- Xianhuan Shen
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China,College of Pharmacy, Jinan University, Guangzhou, China
| | - Xinyi Chen
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China
| | - Jieluan Lu
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China,College of Pharmacy, Jinan University, Guangzhou, China
| | - Qing Chen
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China
| | - Wenzhou Li
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China
| | - Jiahao Zhu
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China,College of Pharmacy, Jinan University, Guangzhou, China
| | - Yaodong He
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China,College of Pharmacy, Jinan University, Guangzhou, China
| | - Huijuan Guo
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China
| | - Chenshu Xu
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China
| | - Xiaomei Fan
- Shenzhen Baoan Women’s and Children’s Hospital, Jinan University, Shenzhen, China,*Correspondence: Xiaomei Fan,
| |
Collapse
|
6
|
Miranda LSDM, de Souza ROMA, Leão RAC, Carneiro PF, Pedraza SF, de Carvalho OV, de Souza SP, Neves RV. Continuous-Flow Sequential Schotten–Baumann Carbamoylation and Acetate Hydrolysis in the Synthesis of Capecitabine. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00206] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Leandro S. de M. Miranda
- Biocatalysis and Organic Synthesis Group, Chemistry Institute, Universidade Federal do Rio de Janeiro, Bloco A 622, 21941-909 Rio de Janeiro-RJ, Brazil
| | - Rodrigo O. M. A. de Souza
- Biocatalysis and Organic Synthesis Group, Chemistry Institute, Universidade Federal do Rio de Janeiro, Bloco A 622, 21941-909 Rio de Janeiro-RJ, Brazil
- Pharmacy School, Universidade Federal do Rio de Janeiro, 21941-909 Rio de Janeiro-RJ, Brazil
| | - Raquel A. C. Leão
- Biocatalysis and Organic Synthesis Group, Chemistry Institute, Universidade Federal do Rio de Janeiro, Bloco A 622, 21941-909 Rio de Janeiro-RJ, Brazil
- Pharmacy School, Universidade Federal do Rio de Janeiro, 21941-909 Rio de Janeiro-RJ, Brazil
| | - Paula F. Carneiro
- Biocatalysis and Organic Synthesis Group, Chemistry Institute, Universidade Federal do Rio de Janeiro, Bloco A 622, 21941-909 Rio de Janeiro-RJ, Brazil
| | - Sergio F. Pedraza
- Nortec Química AS, Distrito Industrial Duque de Caxias, 25250-612 Rio de Janeiro-RJ, Brazil
| | - Otavio V. de Carvalho
- Nortec Química AS, Distrito Industrial Duque de Caxias, 25250-612 Rio de Janeiro-RJ, Brazil
| | - Stefânia P. de Souza
- Biocatalysis and Organic Synthesis Group, Chemistry Institute, Universidade Federal do Rio de Janeiro, Bloco A 622, 21941-909 Rio de Janeiro-RJ, Brazil
| | - Rebeca V. Neves
- Biocatalysis and Organic Synthesis Group, Chemistry Institute, Universidade Federal do Rio de Janeiro, Bloco A 622, 21941-909 Rio de Janeiro-RJ, Brazil
| |
Collapse
|
7
|
Huang XZ, Chen Y, Chen WJ, Zhang X, Wu CC, Wang ZN, Wu J. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer 2018; 142:2567-2577. [PMID: 29355976 DOI: 10.1002/ijc.31269] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 01/13/2018] [Accepted: 01/16/2018] [Indexed: 12/18/2022]
Abstract
Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine-containing chemotherapy. The purpose of this study was to assess the efficacies of various prevention and treatment strategies for capecitabine-induced HFS. Searches of the PubMed and Embase databases were performed to identify relevant studies. The risk ratio (RR) with the corresponding 95% confidence interval (CI) was used as an effect measure to evaluate the efficacies of these prevention and treatment strategies. Publication bias was evaluated using Begg's and Egger's tests. Overall and subgroup analyses were conducted. All statistical analyses were conducted with Stata software version 12.0. Seventeen eligible studies were included. Our results indicated that celecoxib was significantly associated with a lower incidence of grade ≥2 capecitabine-induced HFS without heterogeneity (RR = 0.43, 95% CI = 0.23-0.81, I2 = 0.0%). However, pyridoxine and topical urea/lactic acid were not effective toward preventing capecitabine-induced grade 1, 2, 3, ≥1 or ≥2 HFS. Moreover, pyridoxine was not effective in treating capecitabine-induced HFS. Similar results were obtained by subgroup analysis. Our results indicate that celecoxib has potential prophylactic efficacy for capecitabine-induced HFS. However, pyridoxine and topical urea/lactic acid are not associated with a decrease in the incidence of capecitabine-induced HFS.
Collapse
Affiliation(s)
- Xuan-Zhang Huang
- Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China
| | - You Chen
- The Wenzhou Dental Hospital, 197 Fuqian Street, Lucheng District, Wenzhou City, 325027, People's Republic of China
| | - Wen-Jun Chen
- Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China
| | - Xi Zhang
- Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China
| | - Cong-Cong Wu
- Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China
| | - Zhen-Ning Wang
- Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City, 110001, People's Republic of China
| | - Jian Wu
- Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China
| |
Collapse
|
8
|
Henricks LM, Kienhuis E, de Man FM, van der Veldt AA, Hamberg P, van Kuilenburg AB, van Schaik RH, Lunenburg CA, Guchelaar HJ, Schellens JH, Mathijssen RH. Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. JCO Precis Oncol 2017; 1:1-10. [DOI: 10.1200/po.17.00118] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Linda M. Henricks
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Emma Kienhuis
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Femke M. de Man
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Astrid A.M. van der Veldt
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Paul Hamberg
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - André B.P. van Kuilenburg
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Ron H.N. van Schaik
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Carin A.T.C. Lunenburg
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Henk-Jan Guchelaar
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Jan H.M. Schellens
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| | - Ron H.J. Mathijssen
- Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
9
|
Henricks LM, Siemerink EJ, Rosing H, Meijer J, Goorden SM, Polstra AM, Zoetekouw L, Cats A, Schellens JH, van Kuilenburg AB. Capecitabine-based treatment of a patient with a novelDPYDgenotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer 2017; 142:424-430. [DOI: 10.1002/ijc.31065] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 08/16/2017] [Accepted: 09/08/2017] [Indexed: 01/30/2023]
Affiliation(s)
- Linda M. Henricks
- Division of Pharmacology and Division of Clinical Pharmacology, Department of Medical Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands
| | - Ester J.M. Siemerink
- Department of Internal Medicine; Ziekenhuis Groep Twente (ZGT); Hengelo The Netherlands
| | - Hilde Rosing
- Department of Pharmacy and Pharmacology; The Netherlands Cancer Institute; Amsterdam The Netherlands
| | - Judith Meijer
- Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics; Academic Medical Center, University of Amsterdam; Amsterdam The Netherlands
| | - Susan M.I. Goorden
- Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics; Academic Medical Center, University of Amsterdam; Amsterdam The Netherlands
| | - Abeltje M. Polstra
- Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics; Academic Medical Center, University of Amsterdam; Amsterdam The Netherlands
- Department of Clinical Genetics; VU University Medical Center; Amsterdam The Netherlands
| | - Lida Zoetekouw
- Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics; Academic Medical Center, University of Amsterdam; Amsterdam The Netherlands
| | - Annemieke Cats
- Department of Gastrointestinal Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands
| | - Jan H.M. Schellens
- Division of Pharmacology and Division of Clinical Pharmacology, Department of Medical Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands
- Utrecht Institute for Pharmaceutical Sciences, Utrecht University; Utrecht The Netherlands
| | - André B.P. van Kuilenburg
- Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics; Academic Medical Center, University of Amsterdam; Amsterdam The Netherlands
| |
Collapse
|
10
|
Abstract
Cancer treatment is becoming more and more individually based as a result of the large inter-individual differences that exist in treatment outcome and toxicity when patients are treated using population-based drug doses. Polymorphisms in genes encoding drug-metabolizing enzymes and transporters can significantly influence uptake, metabolism, and elimination of anticancer drugs. As a result, the altered pharmacokinetics can greatly influence drug efficacy and toxicity. Pharmacogenetic screening and/or drug-specific phenotyping of cancer patients eligible for treatment with chemotherapeutic drugs, prior to the start of anticancer treatment, can identify patients with tumors that are likely to be responsive or resistant to the proposed drugs. Similarly, the identification of patients with an increased risk of developing toxicity would allow either dose adaptation or the application of other targeted therapies. This review focuses on the role of genetic polymorphisms significantly altering the pharmacokinetics of anticancer drugs. Polymorphisms in DPYD, TPMT, and UGT1A1 have been described that have a major impact on the pharmacokinetics of 5-fluorouracil, mercaptopurine, and irinotecan, respectively. For other drugs, however, the association of polymorphisms with pharmacokinetics is less clear. To date, the influence of genetic variations on the pharmacokinetics of the increasingly used monoclonal antibodies has hardly been investigated. Some studies indicate that genes encoding the Fcγ-receptor family are of interest, but more research is needed to establish if screening before the start of therapy is beneficial. Considering the profound impact of polymorphisms in drug transporters and drug-metabolizing enzymes on the pharmacokinetics of chemotherapeutic drugs and hence, their toxicity and efficacy, pharmacogenetic and pharmacokinetic profiling should become the standard of care.
Collapse
Affiliation(s)
| | | | - André B P van Kuilenburg
- Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Emma Children's Hospital, F0-220, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
| |
Collapse
|
11
|
Wang YL, Hsu LF. Evaluating the Feasibility of Use of a Foreign Reference Product for Generic Drug Applications: A Retrospective Pilot Study. Eur J Drug Metab Pharmacokinet 2017; 42:935-942. [PMID: 28283987 DOI: 10.1007/s13318-017-0409-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND OBJECTIVES The adoption of a domestic reference product in bioequivalence (BE) studies for generic drug applications is required by some countries. The objective of this study is to assess the feasibility of this by investigating whether innovative products from different countries are bioequivalent. METHODS Data were collected from all generic drug applications received by the Taiwan regulatory authority 2012-2016. If a submission package contained BE studies, that generic product was compared separately with different reference products, and the resulting data included in this analysis. A method of adjusted indirect comparison was used to evaluate the BE of reference products from different sources. The relationship between in vitro dissolution and in vivo BE was also explored. RESULTS The present study included 10 drugs and a total of 11 comparisons. Seven comparisons for maximum concentration (C max) (63.6%) and all comparisons (100.0%) for area under the curve up to last measurable time point (AUC) complied with the BE criterion. Similar in vitro dissolution profiles were observed in all comparisons. Among the comparisons that failed to demonstrate BE, only one was considered to be possibly related to product difference, with point estimates of indirect comparison for C max significantly greater than unity (22%). Discordance between in vitro and in vivo observations was probably due to either drugs with highly variable properties or a lack of discriminatory dissolution testing method. CONCLUSIONS Although this retrospective analysis only included a few drugs and product formulation types, i.e., immediate release, delayed release, and orally disintegrating tablet, these preliminary results suggest that using a foreign reference product in BE studies for generic drug applications could be a feasible approach, but with some restrictions: comparable dissolution profiles, same innovator company, same size, weight, and type of coating as the domestic reference product, etc. Further investigations for other complex formulations are required.
Collapse
Affiliation(s)
- Yi-Lin Wang
- Division of Pharmaceutical Science, Center for Drug Evaluation (CDE), 3F, No.465, Sec.6, Zhongxiao E. Rd., Taipei, 11557, Taiwan
| | - Li-Feng Hsu
- Division of Pharmaceutical Science, Center for Drug Evaluation (CDE), 3F, No.465, Sec.6, Zhongxiao E. Rd., Taipei, 11557, Taiwan.
| |
Collapse
|
12
|
Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome. Chem Res Toxicol 2016; 29:1591-1601. [PMID: 27631426 DOI: 10.1021/acs.chemrestox.6b00215] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Yan Lou
- The
First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310000, People’s Republic of China
| | - Qian Wang
- The
First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310000, People’s Republic of China
| | - Jinqi Zheng
- Zhejiang Institute for Food and Drug Control, Hangzhou, Zhejiang 310004, People’s Republic of China
| | - Haihong Hu
- Laboratory
of Pharmaceutical Analysis and Drug Metabolism, Zhejiang Province
Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
| | - Lin Liu
- The
First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310000, People’s Republic of China
| | - Dongsheng Hong
- The
First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310000, People’s Republic of China
| | - Su Zeng
- Laboratory
of Pharmaceutical Analysis and Drug Metabolism, Zhejiang Province
Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
| |
Collapse
|
13
|
Li Z, Guo Y, Yu Y, Xu C, Xu H, Qin J. Assessment of metabolism-dependent drug efficacy and toxicity on a multilayer organs-on-a-chip. Integr Biol (Camb) 2016; 8:1022-1029. [DOI: 10.1039/c6ib00162a] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
This work presents a new and multifunctional organs-on-a-chip device that allows for the characterization of the multi-step metabolism processes of pro-drug CAP in liver cells and its resultant efficacy in multiple target cells simultaneously and quantitatively.
Collapse
Affiliation(s)
- Zhongyu Li
- Division of Biotechnology
- Dalian Institute of Chemical Physics
- Chinese Academy of Sciences
- China
- University of Chinese Academy of Sciences
| | - Yaqiong Guo
- Division of Biotechnology
- Dalian Institute of Chemical Physics
- Chinese Academy of Sciences
- China
- University of Chinese Academy of Sciences
| | - Yue Yu
- Division of Biotechnology
- Dalian Institute of Chemical Physics
- Chinese Academy of Sciences
- China
- University of Chinese Academy of Sciences
| | - Cong Xu
- Division of Biotechnology
- Dalian Institute of Chemical Physics
- Chinese Academy of Sciences
- China
- University of Chinese Academy of Sciences
| | - Hui Xu
- Division of Biotechnology
- Dalian Institute of Chemical Physics
- Chinese Academy of Sciences
- China
- University of Chinese Academy of Sciences
| | - Jianhua Qin
- Division of Biotechnology
- Dalian Institute of Chemical Physics
- Chinese Academy of Sciences
- China
| |
Collapse
|